Solorank.ai
Login

Cached score snapshot

US.CRL · Charles River Laboratories

110分制 41.6/110；5D動能v2 0/50；排序分 41.6/160 · Incomplete inputs

Back to ranking Open volume snapshot
Ranking score 41.6/160
Main score 41.6/110
5D momentum v2 0/50
Rank #473
Setup grade F 18.5

Score breakdown

避免

Medium twelvedata

Score and price trend

F 18.5 Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 06-17 07-31 09-14 10-05 10-23 $166.51$256.47$346.43 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.34 · anchors 120 +0.79% -1.55% / +3.60% 56.3% 2.5% Actual outcome pending · 0 / 3 bars observed
30D observation +7.97% +0.80% / +14.65% 80% 10% Actual outcome pending · 0 / 30 bars observed
Historical projection 10D n=160 +0.79% -1.27% / +3.81% 59.4% 4.4% Actual outcome pending · 0 / 10 bars observed

歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。

2026-06-17 → 2026-10-23 · 120 archived points · 2 Improving turn signal · 4 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 41.6
Display grade 避免
Model version cursor_18_27_news_v2_160
Main score 41.6/110 (避免)
5D momentum v2 0/50 (無)
Score with momentum v2 41.6/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Incomplete score

此 snapshot 已計出評分，但以下輸入仍不完整；缺失維度以 0 分處理，請留意 audit 明细。

  • VIX_MISSING: VIX market context is required for market environment scoring

Market inputs

Bar count 60
ma20 287.8155
ma50 258.889
close 278.26
prevClose 273
avgVolume20 827053
volumeRatio 0.93
changePercent 1.93

Metrics snapshot

close 278.26
volume 767554
changePercent 1.93

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 41.6/110
Main rating 避免
5D momentum v2 0/50
Score with momentum v2 41.6/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 1.5/5 · 較差
Dimension score 1.5/5
Dimension grade 較差

Sub-items

pbPoints 0.2
pePoints 0
epsPoints 0
roePoints 0
debtPoints 0.4
marginPoints 0
turnoverUsdM 213.5796
volumePoints 0.5
revenuePoints 0
dividendPoints 0
marketCapPoints 0.4

資金流 — 6/20 · 較差
Dimension score 6/20
Dimension grade 較差

Sub-items

cmfPoints 0.8
mfiPoints 1.6
obvPoints 0.8
vwapPoints 0.8

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.CRL
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 6.6/15 · 較差
Dimension score 6.6/15
Dimension grade 較差

Sub-items

vix

score 0

details

source twelvedata+fred
missing true
vixClose n/a

trend

score 2.8

details

qqq

ma20 715.668
ma50 710.4064
name QQQ
close 714.88
points 1.4

spy

ma20 766.879
ma50 758.6164
name SPY
close 764.29
points 1.4
source twelvedata+fred
atrPct 2.8509
atrPoints 3
cciPoints 0.8
vixPoints 0
marketTrendPoints 2.8

催化劑 — 2/20 · 較差
Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 7
catalystCount 0
catalystPoints 2

風險管理 — 6.6/10 · 一般
Dimension score 6.6/10
Dimension grade 一般

Sub-items

position

score 1.4

details

atrPct 2.8509
turnoverUsdM 213.5796
liquidityPoints 0.4
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.CRL
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 262.3942

strength_details

ma_score 1.5
atr_score 2
rsi_score 2.5
macd_score 1.5
volume_score 1
market_adjustment 1
risk_reward_ratio 1.1
stop_loss_percent 5.7
take_profit_price 295.091
target_multiplier 1.9
technical_strength 1.68
take_profit_percent 6
positionPoints 1.4
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 5.7018
diversificationPoints 2

技術信號 — 14.9/30 · 較差
Dimension score 14.9/30
Dimension grade 較差

Sub-items

bbPoints 2.4
adxPoints 3
sarPoints 1.2
vcpPoints 1
macdPoints 2.4

vcpPayload

vcp_pass false
vcp_score 1
vcp_reason 跌縮量(近10日6日)；站上MA50；Ready=N；Confirm=N

vcp_metrics

up_days 2
vol_ref 903470
down_days 7
vcp_ready false
above_ma50 true
avg_vol_10 762770
avg_vol_20 841420
avg_vol_30 903470
range_pct_10 0.1123
range_pct_20 0.1123
range_pct_30 0.2729
up_expand_ok false
lookback_used 59
near_20d_high false
contraction_ok false
down_shrink_ok true
up_expand_days 0
breakout_20d_ok false
vol_ratio_10_30 0.8443
dist_to_20d_high 0.0826
down_shrink_days 6
breakout_level_20d 303.31
vcp_breakout_confirm false
contraction_ratio_10_30 0.4116
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction false
kdjAdxPoints 0.5
rsiKdjPoints 1.6
volumeWeight 2
maCrossPoints 1.6
shortRsiPoints 0
shortMacdPoints 0.4
volConfirmPoints 0
volumePointsTechnical 0.8

情緒分析 — 4/10 · 較差
Dimension score 4/10
Dimension grade 較差

Sub-items

sentiment

score 4

details

source finnhub_news_keyword_model
articleCount 7
negativeHits 0
positiveHits 3
sentimentScoreRaw 1

sentimentData

raw {"id":141437887,"url":"https://finnhub.io/api/news?id=570f6ef30a3ed4013ac09e1fb6def884e127b5fc19628370d1cc6637b2a090ce","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.","category":"company","datetime":1788535828,"headline":"Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?"}, {"id":141370262,"url":"https://finnhub.io/api/news?id=7d5ba9371d1930eef6ddb802d9e400ef4e1043175bf691dbcc69f8abd1c72516","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.","category":"company","datetime":1788276600,"headline":"Is This the Right Time to Add CRL Stock to Your Portfolio?"}, {"id":141336294,"url":"https://finnhub.io/api/news?id=ef8df3fc5c0b2610ad30373b2df3764d1ef0c4b3d8b380e888a27cf084572b31","image":"","source":"Fintel","related":"CRL","summary":"","category":"company","datetime":1787909718,"headline":"Charles River Laboratories International (CRL) Price Target Increased by 17.31% to 274.25"}, {"id":141285572,"url":"https://finnhub.io/api/news?id=af0b40c17707cc8a82f48cd3a27bf7abe05443aaf30a2dfc23afab530bdff260","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Earlier this week, Medigen Vaccine Biologics Corp. announced a collaboration with Charles River Laboratories International to characterize and validate the virus seed bank for its next-generation multivalent enterovirus vaccine, with Charles River providing advanced analytical support including Next-Generation Sequencing for key Chemistry, Manufacturing, and Controls activities. The partnership highlights Charles River’s role as a specialized partner for complex biologics testing and...","category":"company","datetime":1787382551,"headline":"Does Charles River (CRL)–Medigen Vaccine Work Sharpen the Case for Its Complex Biologics Edge?"}, {"id":141285581,"url":"https://finnhub.io/api/news?id=77be90221c348c69061a47943095f6b35c8fee65f87bfe82e289e57d88152193","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River Laboratories International (NYSE:CRL) and Medigen Vaccine Biologics announced a collaboration to develop next-generation enterovirus vaccines using advanced analytics and next-generation sequencing. The partnership focuses on using detailed analytical methods to support faster vaccine development timelines and regulatory compliance. Both companies plan to apply novel testing approaches that aim to reduce reliance on animal studies in future vaccine programs. The agreement is...","category":"company","datetime":1787357537,"headline":"Why Is Charles River Laboratories International (CRL) Pushing Deeper Into Vaccine Development?"}, {"id":141282338,"url":"https://finnhub.io/api/news?id=3046de6b1d88ffc7420634e357f1d3676b81f55e4482259675c37a13227475f5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.","category":"company","datetime":1787326620,"headline":"CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?"}, {"id":141202709,"url":"https://finnhub.io/api/news?id=0efb5a2b6093453effc7803e6c9eff82103c331549bf3569fafc3ce671fb0c49","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Organic revenue returned to growth as biopharmaceutical demand strengthened.","category":"company","datetime":1786543990,"headline":"Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript"}
raw_source {"id":142084682,"url":"https://finnhub.io/api/news?id=6ef799272bb862265c32e71a2510258b2a007c8e9d8289de2feea83698d663a9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Here is how Amgen (AMGN) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.","category":"company","datetime":1789134002,"headline":"Are Medical Stocks Lagging Amgen (AMGN) This Year?"}, {"id":142080461,"url":"https://finnhub.io/api/news?id=3cba58b7a38a0d0ac5cb9d20d30ee129c242160688a84c9d2101067566358306","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"WILMINGTON, Mass., September 11, 2026--Charles River Laboratories to Present at Morgan Stanley and Baird Conferences","category":"company","datetime":1789128000,"headline":"Charles River Laboratories to Present at Morgan Stanley and Baird Conferences"}, {"id":142091518,"url":"https://finnhub.io/api/news?id=e5b70d2ca4fc83e9521085cc99f6fcc54c29dae0cb4abe6829850b59a487c765","image":"","source":"Benzinga","related":"CRL","summary":"Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $300 to $320.","category":"company","datetime":1789126295,"headline":"Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $320"}, {"id":141951308,"url":"https://finnhub.io/api/news?id=c3eedd324610a4d2372d995fee82bd5c98d436e6c2ab5b0c58af6ad0bfd79f9d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"WILMINGTON, Mass., September 08, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) has successfully implemented its Endosafe® Cartridge Technology Automated Manufacturing Suite, a significant advancement in bacterial endotoxin testing cartridge production that expands in-process inspection and digital traceability, strengthens manufacturing controls and increases production capacity.","category":"company","datetime":1788868800,"headline":"Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite"}, {"id":141913510,"url":"https://finnhub.io/api/news?id=93030636154aeb4442631985be95aeeb84233bfcad77a6092698cf29fcc0784c","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2238217382/image_2238217382.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"CRL","summary":"Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation.","category":"company","datetime":1788848276,"headline":"Health Care's Next Act: Tailwinds Emerging Across R&D Cycle"}, {"id":141437887,"url":"https://finnhub.io/api/news?id=570f6ef30a3ed4013ac09e1fb6def884e127b5fc19628370d1cc6637b2a090ce","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.","category":"company","datetime":1788535828,"headline":"Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?"}, {"id":141370261,"url":"https://finnhub.io/api/news?id=dccb73f21d41e94b3ecd3b16b380aa2067c9f976406280e57a6c3ae7664bd5a6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"CRAI gains from strong advisory demand, a diverse client base and specialist talent, but rising costs and tight liquidity pose risks.","category":"company","datetime":1788278340,"headline":"Here's Why You Should Hold Charles River Stock in Your Portfolio Now"}, {"id":141370262,"url":"https://finnhub.io/api/news?id=7d5ba9371d1930eef6ddb802d9e400ef4e1043175bf691dbcc69f8abd1c72516","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.","category":"company","datetime":1788276600,"headline":"Is This the Right Time to Add CRL Stock to Your Portfolio?"}, {"id":141336294,"url":"https://finnhub.io/api/news?id=ef8df3fc5c0b2610ad30373b2df3764d1ef0c4b3d8b380e888a27cf084572b31","image":"","source":"Fintel","related":"CRL","summary":"","category":"company","datetime":1787909718,"headline":"Charles River Laboratories International (CRL) Price Target Increased by 17.31% to 274.25"}, {"id":141365553,"url":"https://finnhub.io/api/news?id=fdc5dcdc431b9ef146e761d842d30c65873936be48b831238710ef6a9c07f771","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Opportunities center on non-animal, pharma and regulatory testing, driven by organ-on-chip, organoids, AI biosimulation, genomics and in vitro toxicity platforms.Dublin, Aug. 27, 2026 (GLOBE NEWSWIRE) -- The \"Animal Testing and Non-Animal Alternative Testing Global Market Opportunities and Strategies to 2035\" has been added to ResearchAndMarkets.com's offering. The latest animal testing and non-animal alternative testing market report provides a comprehensive analysis of industry performance fro","category":"company","datetime":1787831520,"headline":"Animal Testing and Non-Animal Alternative Testing Market Outlook 2025-2035 - Featuring Profiles of Charles River Laboratories, Labcorp, and Eurofins Scientific"}, {"id":141365554,"url":"https://finnhub.io/api/news?id=9b4143fb26738fb4ce760aa104946f153b883c1808ce5fea5f547950c7d60d69","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River Laboratories has significantly outperformed the market, while strong guidance and a bullish analyst outlook support continued optimism.","category":"company","datetime":1787751811,"headline":"Is Wall Street Bullish or Bearish on Charles River Laboratories Stock?"}, {"id":141324273,"url":"https://finnhub.io/api/news?id=03721ff268f5dbbeade78dfd1e473153bf81c7da1a58b90d820bc733d942d886","image":"https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536","source":"Benzinga","related":"CRL","summary":"Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.75% on an annualized basis producing an average annual return of 15.76%. Currently, Charles River has a market capitalization of $15.22","category":"company","datetime":1787675434,"headline":"Here's How Much $100 Invested In Charles River 15 Years Ago Would Be Worth Today"}, {"id":141365555,"url":"https://finnhub.io/api/news?id=bb316e03900c98af836f471c4cf8f628d54928ccd4e2251213ea8fb7f392281b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Here is how Cardiol Therapeutics Inc. (CRDL) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.","category":"company","datetime":1787668803,"headline":"Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?"}, {"id":141363104,"url":"https://finnhub.io/api/news?id=6f5f1c3e39904371e861a27af556e7dccd9d7f4859716741bd9eb776c40e458f","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.","category":"company","datetime":1787660324,"headline":"3 Inflated Stocks We Approach with Caution"}, {"id":141313731,"url":"https://finnhub.io/api/news?id=515bc7cdf58d72a1174672bd595355a9f13d453d64545924216c27831956087e","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"CRL","summary":"Ariel Investments' 13F portfolio rose to $10.03B in Q2 2026, with 27 core positions, each over 2% of assets. Read more on the portfolio here.","category":"company","datetime":1787608034,"headline":"Tracking John Rogers' Ariel Investments Portfolio - Q2 2026 Update"}, {"id":141285572,"url":"https://finnhub.io/api/news?id=af0b40c17707cc8a82f48cd3a27bf7abe05443aaf30a2dfc23afab530bdff260","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Earlier this week, Medigen Vaccine Biologics Corp. announced a collaboration with Charles River Laboratories International to characterize and validate the virus seed bank for its next-generation multivalent enterovirus vaccine, with Charles River providing advanced analytical support including Next-Generation Sequencing for key Chemistry, Manufacturing, and Controls activities. The partnership highlights Charles River’s role as a specialized partner for complex biologics testing and...","category":"company","datetime":1787382551,"headline":"Does Charles River (CRL)–Medigen Vaccine Work Sharpen the Case for Its Complex Biologics Edge?"}, {"id":141285581,"url":"https://finnhub.io/api/news?id=77be90221c348c69061a47943095f6b35c8fee65f87bfe82e289e57d88152193","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River Laboratories International (NYSE:CRL) and Medigen Vaccine Biologics announced a collaboration to develop next-generation enterovirus vaccines using advanced analytics and next-generation sequencing. The partnership focuses on using detailed analytical methods to support faster vaccine development timelines and regulatory compliance. Both companies plan to apply novel testing approaches that aim to reduce reliance on animal studies in future vaccine programs. The agreement is...","category":"company","datetime":1787357537,"headline":"Why Is Charles River Laboratories International (CRL) Pushing Deeper Into Vaccine Development?"}, {"id":141282338,"url":"https://finnhub.io/api/news?id=3046de6b1d88ffc7420634e357f1d3676b81f55e4482259675c37a13227475f5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.","category":"company","datetime":1787326620,"headline":"CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?"}, {"id":141285574,"url":"https://finnhub.io/api/news?id=d55e1da5409b429b35a7e8668915c0b4b965ccb81c477b45942733fffe190b30","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Investors need to pay close attention to CRL stock based on the movements in the options market lately.","category":"company","datetime":1787326140,"headline":"Are Options Traders Betting on a Big Move in Charles River Stock?"}, {"id":141285575,"url":"https://finnhub.io/api/news?id=1e12ffa39729ca80a074f28e25ebc90e0f13ac69e39100a037ee9c241e4da6e5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"CRL's shares have surged 88.6% in a year as DSA returns to organic growth, bookings climb and new testing initiatives broaden its strategy.","category":"company","datetime":1787323800,"headline":"Charles River Gains 88.6% in a Year: What's Driving the Rally?"}, {"id":141285576,"url":"https://finnhub.io/api/news?id=b2b5eccf3c195c8eeeeab121ada79465da1aee4e17871e56b32bb091bbe98e1b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"WILMINGTON, Mass., August 20, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) and Medigen Vaccine Biologics Corp. (MVC) collaborate on the characterization and validation of the virus seed bank for MVC's next-generation multivalent enterovirus vaccine. Charles River will leverage its advanced analytical platforms, including Next-Generation Sequencing (NGS), to support critical steps of Chemistry, Manufacturing, and Controls (CMC) activities for MVC’s next-generation multivalent","category":"company","datetime":1787230800,"headline":"Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing"}, {"id":141262451,"url":"https://finnhub.io/api/news?id=a978100f9c3dbfb785d08bbc780cce434527e9bc36bd7a900f59c0d83731d12b","image":"","source":"Benzinga","related":"CRL","summary":"Collaboration leverages NGS technologies to accelerate high-quality vaccine development, support global regulatory readiness, and help reduce animal testingCharles River Laboratories International, Inc. (NYSE:CRL) and","category":"company","datetime":1787213070,"headline":"Charles River Laboratories And Medigen Vaccine Biologics Collaborate On Characterization And Validation Of Virus Seed Bank For MVC's Next-Gen Multivalent Enterovirus Vaccine"}, {"id":141278737,"url":"https://finnhub.io/api/news?id=67621dd00d7b4422294b7c05c38a9ef3f25ba0e393e2e079e5179b2aacf01c1b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Opportunities span AI-driven protein design and structure prediction, precision therapeutics, engineered biologics and vaccines, synthetic biology, novel enzymes, high-throughput screening, and advanced computational modeling, with Asia-Pacific offering expansion potential. Protein Design and Engineering Market Protein Design and Engineering Market Dublin, Aug. 19, 2026 (GLOBE NEWSWIRE) -- The \"Protein Design and Engineering Market Global Report 2026\" has been added to ResearchAndMarkets.com's o","category":"company","datetime":1787153280,"headline":"Protein Design & Engineering Market Global Report 2026: Evaluating AI Platforms, Rational Design, Directed Evolution, and Strategies of Lonza, Thermo Fisher, GenScript, and Charles River"}, {"id":141285582,"url":"https://finnhub.io/api/news?id=f2ffc4928df30f512c782bc6b60e29e580fed74bfd7e67ea7c362ea378082700","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.","category":"company","datetime":1786892220,"headline":"1 Mid-Cap Stock with Exciting Potential and 2 Facing Challenges"}, {"id":141227357,"url":"https://finnhub.io/api/news?id=2c836453d3e6f0af9a9702b3e6d516f9c1819c14ee6ffb3301e0bfa804000082","image":"https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536","source":"Benzinga","related":"CRL","summary":"Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.07% on an annualized basis producing an average annual return of 15.79%. Currently, Charles River has a market capitalization of $14.32","category":"company","datetime":1786731338,"headline":"If You Invested $100 In Charles River Stock 15 Years Ago, You Would Have This Much Today"}, {"id":141215096,"url":"https://finnhub.io/api/news?id=7b5a09f8c6c584297399c2fb76a48bf64775c609a21dbfb5f5ace62915a2d7ec","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Charles River Laboratories’ second quarter results were shaped by recovering biopharmaceutical demand and the impact of portfolio streamlining. Management highlighted that the rebound was most evident in the Discovery and Safety Assessment (DSA) segment, where net book-to-bill reached a four-year high and organic revenue growth turned positive for the first time since 2023. CEO Birgit Girshick pointed to an uptick in proposal activity and improved funding for small and midsize biotech clients as","category":"company","datetime":1786687500,"headline":"5 Insightful Analyst Questions From Charles River Laboratories’s Q2 Earnings Call"}, {"id":141202709,"url":"https://finnhub.io/api/news?id=0efb5a2b6093453effc7803e6c9eff82103c331549bf3569fafc3ce671fb0c49","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"CRL","summary":"Organic revenue returned to growth as biopharmaceutical demand strengthened.","category":"company","datetime":1786543990,"headline":"Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript"}
data_source finnhub_news_keyword_model
article_count 7
negative_hits 0
positive_hits 3
recomputed_at_score true
sentiment_score_raw 1
source_article_count 27
discarded_article_count 20
sentimentPoints 4

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 1.5 5/110 30% 1.5
資金流 6 20/110 30% 6
市場環境 6.6 15/110 44% 6.6
催化劑 2 20/110 10% 2
風險管理 6.6 10/110 66% 6.6
技術信號 14.9 30/110 49.67% 14.9
情緒分析 4 10/110 40% 4

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 0/50
ret_5d -0.0514
max_score 50
max_total 50
raw_total 0
vcp_bonus 0
vol_ratio 0.9122
ret_points 0
vol_points 0
range_ratio 0.5792
volat_points 0
day_range_pct 0.0171
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 0
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.4

details

atrPct 2.8509
turnoverUsdM 213.5796
liquidityPoints 0.4
volatilityPoints 1
rrPoints 1.4

stopLevels

symbol US.CRL
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 262.3942

strength_details

ma_score 1.5
atr_score 2
rsi_score 2.5
macd_score 1.5
volume_score 1
market_adjustment 1
risk_reward_ratio 1.1
stop_loss_percent 5.7
take_profit_price 295.091
target_multiplier 1.9
technical_strength 1.68
take_profit_percent 6
positionPoints 1.4
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 5.7018
diversificationPoints 2

Calculation audit log

基本面分析總分: 1.5/5分
資金流分析總分: 6/20分
市場環境分析總分: 6.6/15分
催化劑分析: 2/20分
風險管理總分: 6.6/10分
技術信號分析總分: 14.9/30分
情緒分析: 4/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 100
atr
atr 7.9329
rule ATR / current price; lower volatility scores higher
score 6
atr_pct 2.85
cci
rule Cursor_18.24 CCI bands
level 超買或超賣風險
score 2
value -111.35
cmf
rule Cursor_18.24 CMF bands
level 派發
score 2
value -0.0015
kdj
d 26.68
j 6.89
k 20.08
rule Cursor_18.24 K/D cross
score 0
signal 死叉
mfi
rule Cursor_18.24 MFI bands
level 弱流入
score 4
value 41.18
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 2
trend 資金流出
value 8595154
recentSlope -279344.6
previousSlope 200030
rsi
value 35.62
sar
rule Cursor_18.24 Parabolic SAR
score 4
trend 下降
value 291.442
position SAR喺價上
distancePct 4.74
previousTrend 下降
ma50
value 258.889
macd
macd 5.7001
trend 中性偏多
signal 9.9717
histogram -4.2716
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 2
value 288.139
position <VWAP
consecutiveAbove 0
volume
rule Cursor_18.24 volume ratio
level 無力
ratio 0.93
score 4
avgVolume 827053
currentVolume 767554
derived
ma20 287.8155
ma50 258.889
prevClose 273
avgVolume10 749395
avgVolume20 827053
changePercent 1.93
avgVolumeForScore 827053
ma_cross
ma20 287.8155
ma50 258.889
rule Cursor_18.24 MA20/MA50 cross
cross 多頭
score 4
prevMa20 287.966
prevMa50 257.9056
spreadPct 11.17
isVolumeBreakout false
bollinger
lower 273.0619
upper 302.5692
position 中間
rsi_short
value 25.18
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 0.93

Raw calculation JSON

 
{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.850894744092045,
        "turnoverUsdM": 213.57958371554002,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.CRL",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 262.3942,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 2.5,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.1,
      "stop_loss_percent": 5.7,
      "take_profit_price": 295.091,
      "target_multiplier": 1.9,
      "technical_strength": 1.68,
      "take_profit_percent": 6
    },
    "positionPoints": 1.4,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.70178948818409,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 41.6,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 41.6,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 0
  },
  "market": {
    "ma20": 287.8155,
    "ma50": 258.889,
    "close": 278.26,
    "prevClose": 273,
    "avgVolume20": 827053,
    "volumeRatio": 0.93,
    "changePercent": 1.93
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 0,
    "details": {
      "ret_5d": -0.051440257322643235,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 0,
      "vcp_bonus": 0,
      "vol_ratio": 0.912212688074921,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 0.579225387362869,
      "volat_points": 0,
      "day_range_pct": 0.017142204515841163,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 0,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 41.6,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 1.5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 30,
        "contribution": 1.5
      },
      {
        "raw": 6,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 6.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 44,
        "contribution": 6.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 66,
        "contribution": 6.6
      },
      {
        "raw": 14.9,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 49.67,
        "contribution": 14.9
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 41.6,
    "details": [
      "基本面分析總分: 1.5/5分",
      "資金流分析總分: 6/20分",
      "市場環境分析總分: 6.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.6/10分",
      "技術信號分析總分: 14.9/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 1.5,
      "資金流": 6,
      "市場環境": 6.6,
      "情緒分析": 4,
      "技術信號": 14.9,
      "風險管理": 6.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 7,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 213.57958371554002,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.4
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 1.6,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.CRL",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 2.8,
            "details": {
              "qqq": {
                "ma20": 715.6679992,
                "ma50": 710.4063990999997,
                "name": "QQQ",
                "close": 714.88,
                "points": 1.4
              },
              "spy": {
                "ma20": 766.87899445,
                "ma50": 758.61640102,
                "name": "SPY",
                "close": 764.28998,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.850894744092045,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 2.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 7,
              "negativeHits": 0,
              "positiveHits": 3,
              "sentimentScoreRaw": 1
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141437887,
                "url": "https://finnhub.io/api/news?id=570f6ef30a3ed4013ac09e1fb6def884e127b5fc19628370d1cc6637b2a090ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788535828,
                "headline": "Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?"
              },
              {
                "id": 141370262,
                "url": "https://finnhub.io/api/news?id=7d5ba9371d1930eef6ddb802d9e400ef4e1043175bf691dbcc69f8abd1c72516",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.",
                "category": "company",
                "datetime": 1788276600,
                "headline": "Is This the Right Time to Add CRL Stock to Your Portfolio?"
              },
              {
                "id": 141336294,
                "url": "https://finnhub.io/api/news?id=ef8df3fc5c0b2610ad30373b2df3764d1ef0c4b3d8b380e888a27cf084572b31",
                "image": "",
                "source": "Fintel",
                "related": "CRL",
                "summary": "",
                "category": "company",
                "datetime": 1787909718,
                "headline": "Charles River Laboratories International (CRL) Price Target Increased by 17.31% to 274.25"
              },
              {
                "id": 141285572,
                "url": "https://finnhub.io/api/news?id=af0b40c17707cc8a82f48cd3a27bf7abe05443aaf30a2dfc23afab530bdff260",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Earlier this week, Medigen Vaccine Biologics Corp. announced a collaboration with Charles River Laboratories International to characterize and validate the virus seed bank for its next-generation multivalent enterovirus vaccine, with Charles River providing advanced analytical support including Next-Generation Sequencing for key Chemistry, Manufacturing, and Controls activities. The partnership highlights Charles River’s role as a specialized partner for complex biologics testing and...",
                "category": "company",
                "datetime": 1787382551,
                "headline": "Does Charles River (CRL)–Medigen Vaccine Work Sharpen the Case for Its Complex Biologics Edge?"
              },
              {
                "id": 141285581,
                "url": "https://finnhub.io/api/news?id=77be90221c348c69061a47943095f6b35c8fee65f87bfe82e289e57d88152193",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International (NYSE:CRL) and Medigen Vaccine Biologics announced a collaboration to develop next-generation enterovirus vaccines using advanced analytics and next-generation sequencing. The partnership focuses on using detailed analytical methods to support faster vaccine development timelines and regulatory compliance. Both companies plan to apply novel testing approaches that aim to reduce reliance on animal studies in future vaccine programs. The agreement is...",
                "category": "company",
                "datetime": 1787357537,
                "headline": "Why Is Charles River Laboratories International (CRL) Pushing Deeper Into Vaccine Development?"
              },
              {
                "id": 141282338,
                "url": "https://finnhub.io/api/news?id=3046de6b1d88ffc7420634e357f1d3676b81f55e4482259675c37a13227475f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.",
                "category": "company",
                "datetime": 1787326620,
                "headline": "CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?"
              },
              {
                "id": 141202709,
                "url": "https://finnhub.io/api/news?id=0efb5a2b6093453effc7803e6c9eff82103c331549bf3569fafc3ce671fb0c49",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Organic revenue returned to growth as biopharmaceutical demand strengthened.",
                "category": "company",
                "datetime": 1786543990,
                "headline": "Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript"
              }
            ],
            "raw_source": [
              {
                "id": 142084682,
                "url": "https://finnhub.io/api/news?id=6ef799272bb862265c32e71a2510258b2a007c8e9d8289de2feea83698d663a9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Here is how Amgen (AMGN) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.",
                "category": "company",
                "datetime": 1789134002,
                "headline": "Are Medical Stocks Lagging  Amgen (AMGN) This Year?"
              },
              {
                "id": 142080461,
                "url": "https://finnhub.io/api/news?id=3cba58b7a38a0d0ac5cb9d20d30ee129c242160688a84c9d2101067566358306",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass., September 11, 2026--Charles River Laboratories to Present at Morgan Stanley and Baird Conferences",
                "category": "company",
                "datetime": 1789128000,
                "headline": "Charles River Laboratories to Present at Morgan Stanley and Baird Conferences"
              },
              {
                "id": 142091518,
                "url": "https://finnhub.io/api/news?id=e5b70d2ca4fc83e9521085cc99f6fcc54c29dae0cb4abe6829850b59a487c765",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Evercore ISI Group  analyst Ross Muken   maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $300 to $320.",
                "category": "company",
                "datetime": 1789126295,
                "headline": "Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $320"
              },
              {
                "id": 141951308,
                "url": "https://finnhub.io/api/news?id=c3eedd324610a4d2372d995fee82bd5c98d436e6c2ab5b0c58af6ad0bfd79f9d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass., September 08, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) has successfully implemented its Endosafe® Cartridge Technology Automated Manufacturing Suite, a significant advancement in bacterial endotoxin testing cartridge production that expands in-process inspection and digital traceability, strengthens manufacturing controls and increases production capacity.",
                "category": "company",
                "datetime": 1788868800,
                "headline": "Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite"
              },
              {
                "id": 141913510,
                "url": "https://finnhub.io/api/news?id=93030636154aeb4442631985be95aeeb84233bfcad77a6092698cf29fcc0784c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2238217382/image_2238217382.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation.",
                "category": "company",
                "datetime": 1788848276,
                "headline": "Health Care's Next Act: Tailwinds Emerging Across R&D Cycle"
              },
              {
                "id": 141437887,
                "url": "https://finnhub.io/api/news?id=570f6ef30a3ed4013ac09e1fb6def884e127b5fc19628370d1cc6637b2a090ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788535828,
                "headline": "Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?"
              },
              {
                "id": 141370261,
                "url": "https://finnhub.io/api/news?id=dccb73f21d41e94b3ecd3b16b380aa2067c9f976406280e57a6c3ae7664bd5a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "CRAI gains from strong advisory demand, a diverse client base and specialist talent, but rising costs and tight liquidity pose risks.",
                "category": "company",
                "datetime": 1788278340,
                "headline": "Here's Why You Should Hold Charles River Stock in Your Portfolio Now"
              },
              {
                "id": 141370262,
                "url": "https://finnhub.io/api/news?id=7d5ba9371d1930eef6ddb802d9e400ef4e1043175bf691dbcc69f8abd1c72516",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.",
                "category": "company",
                "datetime": 1788276600,
                "headline": "Is This the Right Time to Add CRL Stock to Your Portfolio?"
              },
              {
                "id": 141336294,
                "url": "https://finnhub.io/api/news?id=ef8df3fc5c0b2610ad30373b2df3764d1ef0c4b3d8b380e888a27cf084572b31",
                "image": "",
                "source": "Fintel",
                "related": "CRL",
                "summary": "",
                "category": "company",
                "datetime": 1787909718,
                "headline": "Charles River Laboratories International (CRL) Price Target Increased by 17.31% to 274.25"
              },
              {
                "id": 141365553,
                "url": "https://finnhub.io/api/news?id=fdc5dcdc431b9ef146e761d842d30c65873936be48b831238710ef6a9c07f771",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Opportunities center on non-animal, pharma and regulatory testing, driven by organ-on-chip, organoids, AI biosimulation, genomics and in vitro toxicity platforms.Dublin, Aug. 27, 2026 (GLOBE NEWSWIRE) -- The \"Animal Testing and Non-Animal Alternative Testing Global Market Opportunities and Strategies to 2035\" has been added to ResearchAndMarkets.com's offering. The latest animal testing and non-animal alternative testing market report provides a comprehensive analysis of industry performance fro",
                "category": "company",
                "datetime": 1787831520,
                "headline": "Animal Testing and Non-Animal Alternative Testing Market Outlook 2025-2035 - Featuring Profiles of Charles River Laboratories, Labcorp, and Eurofins Scientific"
              },
              {
                "id": 141365554,
                "url": "https://finnhub.io/api/news?id=9b4143fb26738fb4ce760aa104946f153b883c1808ce5fea5f547950c7d60d69",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories has significantly outperformed the market, while strong guidance and a bullish analyst outlook support continued optimism.",
                "category": "company",
                "datetime": 1787751811,
                "headline": "Is Wall Street Bullish or Bearish on Charles River Laboratories Stock?"
              },
              {
                "id": 141324273,
                "url": "https://finnhub.io/api/news?id=03721ff268f5dbbeade78dfd1e473153bf81c7da1a58b90d820bc733d942d886",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.75% on an annualized basis producing an average annual return of 15.76%. Currently, Charles River has a market capitalization of $15.22",
                "category": "company",
                "datetime": 1787675434,
                "headline": "Here's How Much $100 Invested In Charles River 15 Years Ago Would Be Worth Today"
              },
              {
                "id": 141365555,
                "url": "https://finnhub.io/api/news?id=bb316e03900c98af836f471c4cf8f628d54928ccd4e2251213ea8fb7f392281b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Here is how Cardiol Therapeutics Inc. (CRDL) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.",
                "category": "company",
                "datetime": 1787668803,
                "headline": "Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?"
              },
              {
                "id": 141363104,
                "url": "https://finnhub.io/api/news?id=6f5f1c3e39904371e861a27af556e7dccd9d7f4859716741bd9eb776c40e458f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.",
                "category": "company",
                "datetime": 1787660324,
                "headline": "3 Inflated  Stocks We Approach with Caution"
              },
              {
                "id": 141313731,
                "url": "https://finnhub.io/api/news?id=515bc7cdf58d72a1174672bd595355a9f13d453d64545924216c27831956087e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "CRL",
                "summary": "Ariel Investments' 13F portfolio rose to $10.03B in Q2 2026, with 27 core positions, each over 2% of assets. Read more on the portfolio here.",
                "category": "company",
                "datetime": 1787608034,
                "headline": "Tracking John Rogers' Ariel Investments Portfolio - Q2 2026 Update"
              },
              {
                "id": 141285572,
                "url": "https://finnhub.io/api/news?id=af0b40c17707cc8a82f48cd3a27bf7abe05443aaf30a2dfc23afab530bdff260",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Earlier this week, Medigen Vaccine Biologics Corp. announced a collaboration with Charles River Laboratories International to characterize and validate the virus seed bank for its next-generation multivalent enterovirus vaccine, with Charles River providing advanced analytical support including Next-Generation Sequencing for key Chemistry, Manufacturing, and Controls activities. The partnership highlights Charles River’s role as a specialized partner for complex biologics testing and...",
                "category": "company",
                "datetime": 1787382551,
                "headline": "Does Charles River (CRL)–Medigen Vaccine Work Sharpen the Case for Its Complex Biologics Edge?"
              },
              {
                "id": 141285581,
                "url": "https://finnhub.io/api/news?id=77be90221c348c69061a47943095f6b35c8fee65f87bfe82e289e57d88152193",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories International (NYSE:CRL) and Medigen Vaccine Biologics announced a collaboration to develop next-generation enterovirus vaccines using advanced analytics and next-generation sequencing. The partnership focuses on using detailed analytical methods to support faster vaccine development timelines and regulatory compliance. Both companies plan to apply novel testing approaches that aim to reduce reliance on animal studies in future vaccine programs. The agreement is...",
                "category": "company",
                "datetime": 1787357537,
                "headline": "Why Is Charles River Laboratories International (CRL) Pushing Deeper Into Vaccine Development?"
              },
              {
                "id": 141282338,
                "url": "https://finnhub.io/api/news?id=3046de6b1d88ffc7420634e357f1d3676b81f55e4482259675c37a13227475f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.",
                "category": "company",
                "datetime": 1787326620,
                "headline": "CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?"
              },
              {
                "id": 141285574,
                "url": "https://finnhub.io/api/news?id=d55e1da5409b429b35a7e8668915c0b4b965ccb81c477b45942733fffe190b30",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Investors need to pay close attention to CRL stock based on the movements in the options market lately.",
                "category": "company",
                "datetime": 1787326140,
                "headline": "Are Options Traders Betting on a Big Move in Charles River Stock?"
              },
              {
                "id": 141285575,
                "url": "https://finnhub.io/api/news?id=1e12ffa39729ca80a074f28e25ebc90e0f13ac69e39100a037ee9c241e4da6e5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "CRL's shares have surged 88.6% in a year as DSA returns to organic growth, bookings climb and new testing initiatives broaden its strategy.",
                "category": "company",
                "datetime": 1787323800,
                "headline": "Charles River Gains 88.6% in a Year: What's Driving the Rally?"
              },
              {
                "id": 141285576,
                "url": "https://finnhub.io/api/news?id=b2b5eccf3c195c8eeeeab121ada79465da1aee4e17871e56b32bb091bbe98e1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "WILMINGTON, Mass., August 20, 2026--Charles River Laboratories International, Inc. (NYSE: CRL) and Medigen Vaccine Biologics Corp. (MVC) collaborate on the characterization and validation of the virus seed bank for MVC's next-generation multivalent enterovirus vaccine. Charles River will leverage its advanced analytical platforms, including Next-Generation Sequencing (NGS), to support critical steps of Chemistry, Manufacturing, and Controls (CMC) activities for MVC’s next-generation multivalent",
                "category": "company",
                "datetime": 1787230800,
                "headline": "Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing"
              },
              {
                "id": 141262451,
                "url": "https://finnhub.io/api/news?id=a978100f9c3dbfb785d08bbc780cce434527e9bc36bd7a900f59c0d83731d12b",
                "image": "",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Collaboration leverages NGS technologies to accelerate high-quality vaccine development, support global regulatory readiness, and help reduce animal testingCharles River Laboratories International, Inc. (NYSE:CRL) and",
                "category": "company",
                "datetime": 1787213070,
                "headline": "Charles River Laboratories And Medigen Vaccine Biologics Collaborate On Characterization And Validation Of Virus Seed Bank For MVC's Next-Gen Multivalent Enterovirus Vaccine"
              },
              {
                "id": 141278737,
                "url": "https://finnhub.io/api/news?id=67621dd00d7b4422294b7c05c38a9ef3f25ba0e393e2e079e5179b2aacf01c1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Opportunities span AI-driven protein design and structure prediction, precision therapeutics, engineered biologics and vaccines, synthetic biology, novel enzymes, high-throughput screening, and advanced computational modeling, with Asia-Pacific offering expansion potential. Protein Design and Engineering Market Protein Design and Engineering Market Dublin, Aug. 19, 2026 (GLOBE NEWSWIRE) -- The \"Protein Design and Engineering Market Global Report 2026\" has been added to ResearchAndMarkets.com's o",
                "category": "company",
                "datetime": 1787153280,
                "headline": "Protein Design & Engineering Market Global Report 2026: Evaluating AI Platforms, Rational Design, Directed Evolution, and Strategies of Lonza, Thermo Fisher, GenScript, and Charles River"
              },
              {
                "id": 141285582,
                "url": "https://finnhub.io/api/news?id=f2ffc4928df30f512c782bc6b60e29e580fed74bfd7e67ea7c362ea378082700",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.",
                "category": "company",
                "datetime": 1786892220,
                "headline": "1 Mid-Cap Stock with Exciting Potential and 2 Facing Challenges"
              },
              {
                "id": 141227357,
                "url": "https://finnhub.io/api/news?id=2c836453d3e6f0af9a9702b3e6d516f9c1819c14ee6ffb3301e0bfa804000082",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "CRL",
                "summary": "Charles River (NYSE:CRL) has outperformed the market over the past 15 years by 2.07% on an annualized basis producing an average annual return of 15.79%. Currently, Charles River has a market capitalization of $14.32",
                "category": "company",
                "datetime": 1786731338,
                "headline": "If You Invested $100 In Charles River Stock 15 Years Ago, You Would Have This Much Today"
              },
              {
                "id": 141215096,
                "url": "https://finnhub.io/api/news?id=7b5a09f8c6c584297399c2fb76a48bf64775c609a21dbfb5f5ace62915a2d7ec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Charles River Laboratories’ second quarter results were shaped by recovering biopharmaceutical demand and the impact of portfolio streamlining. Management highlighted that the rebound was most evident in the Discovery and Safety Assessment (DSA) segment, where net book-to-bill reached a four-year high and organic revenue growth turned positive for the first time since 2023. CEO Birgit Girshick pointed to an uptick in proposal activity and improved funding for small and midsize biotech clients as",
                "category": "company",
                "datetime": 1786687500,
                "headline": "5 Insightful Analyst Questions From Charles River Laboratories’s Q2 Earnings Call"
              },
              {
                "id": 141202709,
                "url": "https://finnhub.io/api/news?id=0efb5a2b6093453effc7803e6c9eff82103c331549bf3569fafc3ce671fb0c49",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "CRL",
                "summary": "Organic revenue returned to growth as biopharmaceutical demand strengthened.",
                "category": "company",
                "datetime": 1786543990,
                "headline": "Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 7,
            "negative_hits": 0,
            "positive_hits": 3,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1,
            "source_article_count": 27,
            "discarded_article_count": 20
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 14.9,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 1,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1,
            "vcp_reason": "跌縮量(近10日6日)；站上MA50；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 2,
              "vol_ref": 903470,
              "down_days": 7,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 762770,
              "avg_vol_20": 841420,
              "avg_vol_30": 903470,
              "range_pct_10": 0.11230504160479256,
              "range_pct_20": 0.11230504160479256,
              "range_pct_30": 0.2728742804257069,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.8442671035009464,
              "dist_to_20d_high": 0.08258873759519957,
              "down_shrink_days": 6,
              "breakout_level_20d": 303.31,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.4115633083102857
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 1.6,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.850894744092045,
              "turnoverUsdM": 213.57958371554002,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.CRL",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 262.3942,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 2.5,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.1,
            "stop_loss_percent": 5.7,
            "take_profit_price": 295.091,
            "target_multiplier": 1.9,
            "technical_strength": 1.68,
            "take_profit_percent": 6
          },
          "positionPoints": 1.4,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.70178948818409,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.CRL",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 100,
    "atr": {
      "atr": 7.9329,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.85
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -111.35
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0015
    },
    "kdj": {
      "d": 26.68,
      "j": 6.89,
      "k": 20.08,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 41.18
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 8595154,
      "recentSlope": -279344.6,
      "previousSlope": 200030
    },
    "rsi": 35.62,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 291.442,
      "position": "SAR喺價上",
      "distancePct": 4.74,
      "previousTrend": "下降"
    },
    "ma50": 258.889,
    "macd": {
      "macd": 5.700125918806862,
      "trend": "中性偏多",
      "signal": 9.971737120038876,
      "histogram": -4.271611201232014
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 288.139,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.93,
      "score": 4,
      "avgVolume": 827053,
      "currentVolume": 767554
    },
    "derived": {
      "ma20": 287.8155,
      "ma50": 258.889,
      "prevClose": 273,
      "avgVolume10": 749395,
      "avgVolume20": 827053,
      "changePercent": 1.93,
      "avgVolumeForScore": 827053
    },
    "ma_cross": {
      "ma20": 287.8155,
      "ma50": 258.889,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 287.966,
      "prevMa50": 257.9056,
      "spreadPct": 11.17,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 273.0619,
      "upper": 302.5692,
      "position": "中間"
    },
    "rsi_short": 25.18,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.93
    }
  }
}

Raw metrics JSON

 
{
  "close": 278.26,
  "volume": 767554,
  "changePercent": 1.93
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.